Quantitative analysis and clinical application of iris circulation in ischemic retinal disease

Yanwen Jia, Wenwen Xue, Xiaowei Tong, Yulan Wang, Lipu Cui, Haidong Zou, Yanwen Jia, Wenwen Xue, Xiaowei Tong, Yulan Wang, Lipu Cui, Haidong Zou

Abstract

Background: To evaluate quantitative changes in iris blood circulation in patients with ischemic risk.

Methods: This observational case-control study included 79 patients with diabetic retinopathy (DR) and retinal vein occlusion (RVO). The RVO group included 21 patients; the monocular proliferative diabetic retinopathy (PDR) group included 19 patients; the nondiabetic retinopathy (NDR) group included 18 patients; and the healthy control group included 21 healthy controls. In the RVO group, we analyzed RVO affected eyes, RVO contralateral eyes, and healthy control eyes. We also compared eyes with PDR and contralateral eyes without PDR, patients with diabetes mellitus (DM) without DR, and healthy control eyes. The microvascular networks of the iris and retina were analyzed using optical coherence tomography angiography. The analysis included vessel area density (VAD) and vessel skeleton density (VSD) of iris and retina.

Results: In the RVO group, the VAD and VSD of iris in the affected eye were higher than those in contralateral and healthy control eyes, and the VAD and VSD of contralateral eyes were higher than those of healthy control eyes. The retinal blood flow of the RVO eyes was less than that of the contralateral and healthy control eyes, but there were no difference between the contralateral eyes and healthy control eyes. The VAD and VSD of iris in PDR were larger than nonproliferative diabetic retinopathy (NPDR) and the NPDR were larger than NDR. There were no differences between NDR and healthy control eyes. Also, there were no differences among the four groups with respect to retinal blood flow.

Conclusions: Compared with the retina, iris blood circulation quantitative analysis data seem to be more sensitive to ischemia and may be used as a new predictor of ischemic disease, even if further research is needed to better understand the clinical value and importance of this analysis.

Trial registration: The trial is registered with the clinical trial registration number nct03631108 .

Trial registration: ClinicalTrials.gov NCT03631108.

Keywords: Diabetic retinopathy; Iris vessel; Ischemic disease; Optical coherence tomography angiography; Retinal vein occlusion.

Conflict of interest statement

The authors have declared that no conflict of interest exists.

© 2021. The Author(s).

Figures

Fig. 1
Fig. 1
Iris OCTA for a healthy eye, male, 47 years old
Fig. 2
Fig. 2
Iris OCTA for a PDR eye, male, 48 years old
Fig. 3
Fig. 3
Trends of changes in iris vessel area density (VAD) in different segments in different eyes
Fig. 4
Fig. 4
Trends of changes in iris vessel skeleton density (VSD) in different segments in different eyes

References

    1. Allingham MJ, Mettu PS, Cousins SW. Aldosterone as a mediator of severity in retinal vascular disease: evidence and potential mechanisms. Exp Eye Res. 2019;188:107788. doi: 10.1016/j.exer.2019.107788.
    1. Tey KY, Teo K, Tan ACS, Devarajan K, Tan B, Tan J, et al. Optical coherence tomography angiography in diabetic retinopathy: a review of current applications. Eye Vis (Lond) 2019;6:37. doi: 10.1186/s40662-019-0160-3.
    1. Tripathi RC, Li J, Tripathi BJ, Chalam KV, Adamis AP. Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology. 1998;105:232–237. doi: 10.1016/S0161-6420(98)92782-8.
    1. Chalam KV, Brar VS, Murthy RK. Human ciliary epithelium as a source of synthesis and secretion of vascular endothelial growth factor in neovascular glaucoma. JAMA Ophthalmol. 2014;132:1350–1354. doi: 10.1001/jamaophthalmol.2014.2356.
    1. Wang JW, Zhou MW, Zhang X, Huang WB, Gao XB, Wang W, et al. Short-term effect of intravitreal ranibizumab on intraocular concentrations of vascular endothelial growth factor-a and pigment epithelium-derived factor in neovascular glaucoma. Clin Exp Ophthalmol. 2015;43:415–421. doi: 10.1111/ceo.12477.
    1. Rong AJ, Swaminathan SS, Vanner EA, Parrish RK., 2nd Predictors of Neovascular Glaucoma in Central Retinal Vein Occlusion. Am J Ophthalmol. 2019;205:201–202. doi: 10.1016/j.ajo.2019.04.029.
    1. Demeler U, Sautter H. Iris angiography studies in patients with diabetes mellitus. Adv Ophthalmol. 1978;36:233–244.
    1. Paques M, Girmens JF, Riviere E, Sahel J. Dilation of the minor arterial circle of the iris preceding rubeosis iridis during retinal vein occlusion. Am J Ophthalmol. 2004;138:1083–1086. doi: 10.1016/j.ajo.2004.06.080.
    1. Allegrini D, Montesano G, Pece A. Optical coherence tomography angiography in a Normal Iris. Ophthalmic Surg Lasers Imaging Retina. 2016;47:1138–1139. doi: 10.3928/23258160-20161130-08.
    1. A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. The Central Vein Occlusion Study Group N report. Ophthalmology. 1995;102:1434–44.
    1. Zhao Q, Yang WL, Wang XN, Wang RK, You QS, Chu ZD, et al. Repeatability and reproducibility of quantitative assessment of the retinal microvasculature using optical coherence tomography angiography based on optical microangiography. Biomed Environ Sci. 2018;31:407–412.
    1. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale: L. Erlbaum Associates; 1988. p. xxi, 567.
    1. Koulisis N, Kim AY, Chu Z, Shahidzadeh A, Burkemper B, Olmos de Koo LC, et al. Quantitative microvascular analysis of retinal venous occlusions by spectral domain optical coherence tomography angiography. PLoS One. 2017;12:e0176404. doi: 10.1371/journal.pone.0176404.
    1. Kang JW, Yoo R, Jo YH, Kim HC. Correlation of microvascular structures on optical coherence tomography angiography with visual acuity in retinal vein occlusion. Retina. 2017;37:1700–1709. doi: 10.1097/IAE.0000000000001403.
    1. Adhi M, Filho MA, Louzada RN, Kuehlewein L, de Carlo TE, Baumal CR, et al. Retinal capillary network and Foveal avascular zone in eyes with vein occlusion and fellow eyes analyzed with optical coherence tomography angiography. Invest Ophthalmol Vis Sci. 2016;57:OCT486–OCT494. doi: 10.1167/iovs.15-18907.
    1. McIntosh RL, Rogers SL, Lim L, Cheung N, Wang JJ, Mitchell P, et al. Natural history of central retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 2010;117:1113–1123. doi: 10.1016/j.ophtha.2010.01.060.
    1. O'Mahoney PR, Wong DT, Ray JG. Retinal vein occlusion and traditional risk factors for atherosclerosis. Arch Ophthalmol. 2008;126:692–699. doi: 10.1001/archopht.126.5.692.
    1. Gouliopoulos N, Siasos G, Moschos MM, Oikonomou E, Rouvas A, Bletsa E, et al. Endothelial dysfunction and impaired arterial wall properties in patients with retinal vein occlusion. Vasc Med. 2020;25:302–308. doi: 10.1177/1358863X20913609.
    1. Wang Q, Chan SY, Yan Y, Yang J, Zhou W, Jonas JB, et al. Optical coherence tomography angiography in retinal vein occlusions. Graefes Arch Clin Exp Ophthalmol. 2018;256:1615–1622. doi: 10.1007/s00417-018-4038-1.
    1. Hirano T, Kitahara J, Toriyama Y, Kasamatsu H, Murata T, Sadda S. Quantifying vascular density and morphology using different swept-source optical coherence tomography angiographic scan patterns in diabetic retinopathy. Br J Ophthalmol. 2019;103:216–221. doi: 10.1136/bjophthalmol-2018-311942.
    1. Kim AY, Chu Z, Shahidzadeh A, Wang RK, Puliafito CA, Kashani AH. Quantifying microvascular density and morphology in diabetic retinopathy using spectral-domain optical coherence tomography angiography. Invest Ophthalmol Vis Sci. 2016;57:362–370. doi: 10.1167/iovs.15-18904.
    1. Brancato R, Bandello F, Lattanzio R. Iris fluorescein angiography in clinical practice. Surv Ophthalmol. 1997;42:41–70. doi: 10.1016/S0039-6257(97)84042-8.
    1. Koz OG, Ozsoy A, Yarangumeli A, Kose SK, Kural G. Comparison of the effects of travoprost, latanoprost and bimatoprost on ocular circulation: a 6-month clinical trial. Acta Ophthalmol Scand. 2007;85:838–843. doi: 10.1111/j.1600-0420.2007.00960.x.
    1. Douros S, Phillips BA, Nadel A, Obstbaum SA. Human vitreal prostaglandin levels and proliferative diabetic retinopathy. Doc Ophthalmol. 2001;103:27–34. doi: 10.1023/A:1017557600233.
    1. Pichi F, Woodstock E, Hay S, Neri P. Optical coherence tomography angiography findings in systemic lupus erythematosus patients with no ocular disease. Int Ophthalmol. 2020;40:2111–2118. doi: 10.1007/s10792-020-01388-3.
    1. Kivlin JD, Biglan AW, Gordon RA, Dobson V, Hardy RA, Palmer EA, et al. Early retinal vessel development and iris vessel dilatation as factors in retinopathy of prematurity. Cryotherapy for retinopathy of prematurity (CRYO-ROP) cooperative group. Arch Ophthalmol. 1996;114:150–154. doi: 10.1001/archopht.1996.01100130144005.
    1. Yang H, Yu PK, Cringle SJ, Sun X, Yu DY. Microvascular network and its endothelial cells in the human Iris. Curr Eye Res. 2018;43:67–76. doi: 10.1080/02713683.2017.1379544.
    1. Iovino C, Peiretti E, Braghiroli M, Tatti F, Aloney A, Lanza M, et al. Imaging of iris vasculature: current limitations and future perspective. Eye (Lond). 2021. 10.1038/s41433-021-01809-2.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren